Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Human Lgr4/GPR48 Antibody, R&D Systems™

Mouse Monoclonal Antibody
Supplier: R&D Systems MAB7750SP
This item is not returnable.
View return policy
Description
Lgr4/GPR48 Monoclonal specifically detects Lgr4/GPR48 in Human samples. It is validated for Flow Cytometry, Blockade of Receptor-ligand Interaction, Immunocytochemistry, CyTOF-ready.Specifications
Lgr4/GPR48 | |
Monoclonal | |
Unconjugated | |
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 μm filtered solution in PBS. with No Preservative | |
GPR48, GPR48G protein-coupled receptor 48, G-protein coupled receptor 48, leucine-rich repeat containing G protein-coupled receptor 4 | |
Mouse | |
Protein A or G purified from hybridoma culture supernatant | |
RUO | |
55366 | |
Reconstitute at 0.5 mg/mL in sterile PBS. | |
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 degreesC as supplied. 1 month, 2 to 8 degreesC under sterile conditions after reconstitution. 6 months, -20 to -70 degreesC under sterile conditions after reconstitution. | |
IgG2b |
Flow Cytometry, Blockade of Receptor-ligand Interaction, Immunocytochemistry, CyTOF | |
852229 | |
Flow Cytometry 0.25 ug/10^6 cells, Blockade of Receptor-ligand Interaction 2.5 ug/mL, Immunocytochemistry 8-25 ug/mL, CyTOF-ready | |
Q9BXB1 | |
LGR4 | |
NS0 mouse myeloma cell line transfected with human Lgr4/GPR48 Met1-Asp951 Accession # Q9BXB1 | |
25 μg | |
Primary | |
Detects human Lgr4/GPR48 in Lgr4-transfected cell-based ELISA. Stains human Lgr4/GPR48 transfected but not irrelevant transfected cells in flow cytometry. | |
Human | |
Purified |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
For Research Use Only
Spot an opportunity for improvement?Share a Content Correction